In last trading session, Avidity Biosciences Inc (NASDAQ:RNA) saw 0.54 million shares changing hands with its beta currently measuring 0.20. Company’s recent per share price level of $6.37 trading at $0.44 or 7.42% at ring of the bell on the day assigns it a market valuation of $472.02M. That closing price of RNA’s stock is at a discount of -304.08% from its 52-week high price of $25.74 and is indicating a premium of 24.33% from its 52-week low price of $4.82. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.68 million shares which gives us an average trading volume of 793.09K if we extend that period to 3-months.
For Avidity Biosciences Inc (RNA), analysts’ consensus is at an average recommendation of a Buy while assigning it a mean rating of 1.00. Splitting up the data highlights that, out of 7 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 7 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -$0.79 in the current quarter.
Avidity Biosciences Inc (NASDAQ:RNA) trade information
Upright in the green during last session for gaining 7.42%, in the last five days RNA remained trading in the green while hitting it’s week-highest on Wednesday, 11/15/23 when the stock touched $6.37 price level, adding 4.64% to its value on the day. Avidity Biosciences Inc’s shares saw a change of -71.29% in year-to-date performance and have moved 16.24% in past 5-day. Avidity Biosciences Inc (NASDAQ:RNA) showed a performance of 15.40% in past 30-days. Number of shares sold short was 11.6 million shares which calculate 15.83 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of $37.00 to the stock, which implies a rise of 82.78% to its current value. Analysts have been projecting $18.00 as a low price target for the stock while placing it at a high target of $71.00. It follows that stock’s current price would drop -1014.6% in reaching the projected high whereas dropping to the targeted low would mean a loss of -182.57% for stock’s current value.
Avidity Biosciences Inc (RNA) estimates and forecasts
Statistics highlight that Avidity Biosciences Inc is scoring comparatively lower than the scores of other players of the relevant industry. The company lost -41.13% of value to its shares in past 6 months, showing an annual growth rate of 13.17% while that of industry is 14.80. Apart from that, the company came raising its revenue forecast for fiscal year 2023. The company is estimating its revenue growth to increase by 10.20% in the current quarter and calculating -14.90% decrease in the next quarter. This year revenue growth is estimated to rise 4.00% from the last financial year’s standing.
6 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of $2.21 million for the same. And 4 analysts are in estimates of company making revenue of $1.29 million in the next quarter that will end on Mar 2024. Company posted $2.77 million and $2.23 million of sales in current and next quarters respectively a year earlier. Analysts are expecting this quarter sales to shrink by -20.20% while estimating it to be -42.20% for the next quarter.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -82.76% during past 5 years.
Avidity Biosciences Inc is more likely to be releasing its next quarterly report in December and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.
Avidity Biosciences Inc (NASDAQ:RNA)’s Major holders
Insiders are in possession of 4.56% of company’s total shares while institution are holding 108.39 percent of that, with stock having share float percentage of 113.57%. Investors also watch the number of corporate investors in a company very closely, which is 108.39% institutions for Avidity Biosciences Inc that are currently holding shares of the company. FMR, LLC is the top institutional holder at RNA for having 10.62 million shares of worth $117.81 million. And as of Jun 29, 2023, it was holding 14.34% of the company’s outstanding shares.
The second largest institutional holder is RTW Investments LP, which was holding about 6.69 million shares on Jun 29, 2023. The number of shares represents firm’s hold over 9.03% of outstanding shares, having a total worth of $74.19 million.
On the other hand, SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF and Price (T.Rowe) New Horizons Fund are the top two Mutual Funds which own company’s shares. As of Aug 30, 2023, the former fund manager was holding 4.62 million shares of worth $34.91 million or 6.23% of the total outstanding shares. The later fund manager was in possession of 3.36 million shares on Jun 29, 2023, making its stake of worth around $37.23 million in the company or a holder of 4.53% of company’s stock.